| Formatted contents note |
Normal breast and developmental disorders -- Reactive and inflammatory conditions of the breast -- Infections of the breast -- Epidemiology of breast cancer and pathology of heritable breast cancer -- Patient safety in breast pathology -- Gross examination of breast specimens -- Sentinel lymph node biopsy -- Breast imaging modalities for pathologists -- Predictive and prognostic marker testing in breast pathology : immunophenotypic subclasses of disease -- Molecular-based testing in breast disease for therapeutic decisions -- Diagnostic immunohistology of the breast -- Fibroepithelial lesions -- Papilloma and papillary lesions -- Adenosis and microglandular adenosis -- Nipple adenoma (florid papillomatosis of the nipple) -- Radial scar -- Myoepithelial lesions of the breast -- Fibrocystic change and usual epithelial hyperplasia of ductal type -- Columnar cell alterations, flat epithelial atypia, and atypical ductal epithelial hyperplasia -- Molecular classification of breast carcinoma -- Lobular neoplasia and invasive lobular carcinoma -- Ductal carcinoma in situ -- Invasive ductal carcinoma of no special type and histologic grade -- Triple-negative and basal-like carcinoma -- Metaplastic breast carcinoma -- Apocrine carcinoma of the breast -- Paget disease of the breast -- Pathology of neoadjuvant therapeutic response of breast carcinoma -- Special types of invasive breast carcinoma : tubular carcinoma, mucinous carcinoma, cribriform carcinoma, micropapillary carcinoma, carcinoma with medullary features -- Rare breast carcinomas : adenoid cystic carcinoma, neuroendocrine carcinoma, secretory carcinoma, carcinoma with osteoclast-like giant cells, lipid-rich carcinoma, and glycogen-rich clear cell carcinoma -- Mesenchymal neoplasms of the breast -- Neoplasia of the male breast -- Breast tumors in children and adolescents -- Tumors of the mammary skin -- Hematopoietic tumors of the breast -- Metastatic tumors in the breast -- Next-generation dna sequencing and the management of patients with clinically advanced breast cancer. |
